Abstract: The angiotensin II type I receptor (AT1R) is involved in the regulation of cardiovascular function. Excessive activation of AT1R by angiotensin II (Ang II) leads to cardiovascular disease and may be involved in the development of insulin resistance and diabetes. Functionally selective Ang II analogues, such as the [Sar1, Ile4, Ile8]-angiotensin II (SII Ang II) analogue, that only activate a subset of signalling networks have been demonstrated to have beneficial effects on cardiovascular function in certain settings, including lowering blood pressure and increasing cardiac performance. Here, we studied the effect of SII Ang II on insulin receptor (IR) signalling and glucose metabolism in primary rat hepatocytes. We show that long-term pre-treatment of hepatocytes with SII Ang II increased insulin-stimulated glycogen synthesis, while Ang II and the AT1R antagonist losartan had no effect. Insulin-stimulated suppression of hepatic glucose output was not affected by Ang II or SII Ang II. It is well known that insulin regulates glycogen synthesis and glucose output through Akt-mediated phosphorylation of glycogen synthase kinase a/b (GSK3a/b) and forkhead box protein O1 (FOXO1), respectively. In line with this, we show that SII Ang II potentiated insulinstimulated phosphorylation of Akt and GSK3a/b, but not FOXO1. Furthermore, we demonstrate that the effect of SII Ang II on insulin-stimulated signalling and glycogen synthesis was dependent on Src and Gaq, as inhibitors of these proteins abolished the potentiating effect of SII Ang II. Thus, our results demonstrate that SII Ang II may have a positive effect on IR signalling and glucose metabolism in hepatocytes.
The liver plays an essential role in maintaining glucose homeostasis. In the postprandial state, the liver takes up glucose and converts it to glycogen, while in the post-absorptive state, the liver liberates glucose by glycogenolysis and gluconeogenesis [1] . These mechanisms are regulated by insulin, and the dysregulation of hepatic glucose metabolism is associated with metabolic disorders such as type 2 diabetes [1] .
In the liver, insulin activates the insulin receptor (IR) leading to phosphorylation and activation of Akt, which is the key kinase in IR signalling and metabolic regulation. Activated Akt in turn phosphorylates and inactivates glycogen synthase kinase a/b (GSK3a/b) that normally inhibits glycogen synthase (GS) [2] . The inactivation of GSK3a/b by insulin and consequent activation of GS leads to an increase in glycogen synthesis. Insulin also inactivates forkhead box protein O1 (FOXO1) through Akt, which leads to inhibition of gluconeogenesis [3, 4] .
Several studies have demonstrated that Ang II via activation of the angiotensin II type 1 receptor (AT1R) may play a role in the development of insulin resistance, a hallmark of type 2 diabetes [5] [6] [7] . AT1R is well known for its profound role in regulating blood pressure and fluid homeostasis [8] . AT1R is also involved in the pathogenesis of medical conditions such as endothelial dysfunction, cardiac hypertrophy and cardiac failure and is therefore a prominent drug target in cardiovascular disease where the use of AT1R blockers and angiotensin-converting enzyme (ACE) inhibitors has been proven effective [8] .
Increased Ang II levels are associated with both development of cardiovascular disease and development of insulin resistance. The TG(mRen2)27 rat model that harbours the mouse renin gene (Ren2) have increased Ang II tissue level, and it has been demonstrated that rats develop hyperinsulinaemia, glucose intolerance, decreased insulin sensitivity and decreased glucose uptake in muscle tissue in addition to developing severe hypertension, left ventricular hypertrophy and cardiac failure [9, 10] . By contrast, inhibition of AT1R not only lowers blood pressure and improves heart function, but may also improve glycaemic control by increasing insulinmediated glucose disposal in hypertensive and/or obese patients, and also improve diabetic nephropathy [11] [12] [13] . Furthermore, clinical studies (post hoc analysis and clinical trials) indicate that long-term treatment of patients with cardiovascular disease with ACE inhibitors or AT1R blockers decreases the risk of new-onset diabetes mellitus by up to 32% [14, 15] .
On the molecular level, activation of AT1R by Ang II decreases insulin-stimulated tyrosine (Tyr) phosphorylation of insulin receptor substrates (IRS) [7, [16] [17] [18] . By inhibiting Tyr phosphorylation of IRS, Ang II leads to impaired insulin-stimulated phosphorylation and activation of Akt [7, [16] [17] [18] , thus demonstrating crosstalk between AT1R and IR signalling networks.
Angiotensin II type 1 receptor signalling is mediated through two principal pathways: 1) the classical Gaq protein-dependent pathway, which leads to accumulation of inositol phosphate, an increase in intracellular calcium and consequently kinase activation, and 2) the alternative pathway mediated by the recruitment of b-arrestin-1 and b-arrestin-2 to the receptor and subsequent kinase activation [19] [20] [21] [22] . The functionally selective agonist [Sar1, Ile4, Ile8]-angiotensin II (SII Ang II) that does not activate the Gaq-dependent pathway robustly while still activating the b-arrestin-mediated pathway has been a useful tool in dissecting the two pathways [23] . It has been demonstrated that the two pathways activate different subsets of signalling networks and lead to different cellular outcome [24] [25] [26] [27] [28] [29] . The activation of the b-arrestin-mediated pathway confers cardioprotection and increases contractility, while signalling through G proteins has been associated with pathological hypertrophy and fibroses [24, 25, [30] [31] [32] . Thus, functionally selective AT1R agonists may offer new treatment options for patients with certain cardiovascular diseases, and a new functionally selective AT1R agonist TRV027 is currently in clinical trial for treatment of acute heart failure [32] .
The effects of functionally selective AT1R agonists on cardiovascular function are well described [24, 25, [30] [31] [32] , but their effect on glucose metabolism has not previously been studied. Here, we report a novel role for the functionally selective agonist SII Ang II in IR signalling and glucose metabolism in primary hepatocytes, where SII Ang II potentiates insulin-stimulated IR signalling and glycogen synthesis. Thus, functionally selective AT1R agonists may potentially have beneficial roles beyond that in the cardiovascular system.
Materials and Methods
Primary hepatocyte culture. Hepatocytes from male Sprague Dawley rats (8 weeks, 200-300 g) were isolated using a standard collagenase perfusion protocol as described in Ref. [33] . In brief, rats were anaesthetized subcutaneously with a mixture of Hypnorm (fentanyl citrate 0.315 mg/ml and fluanisone 10 mg/ml) and Dormicum (midazolam 5 mg/ml). The abdominal cavity was opened and loose ligatures were placed around vena portae and lower and upper vena cava. The canula was inserted into the vena portae and the ligature was tightened. The lower vena cava was cut to allow flow-through. A hole is cut in the heart and a tube inserted into the upper vena cava. Distal end of vena cava was clamped and the liver was perfused with 25 mM HEPES buffer for 10 min. (40 ml/min), followed by perfusion with 200 ml of calcium-containing collagenase buffer (25 mM HEPES buffer supplemented with 2 mM CaCl2 and 0.6 mg/ml collagenase (C-1889, Sigma). Hepatocytes were loosened, filtered and cultured in medium 199 (with 5.5 mM glucose and GlutaMAX, Gibco) supplemented with 100 nM Decadron (MSD), 1% (v/v) penicillin/ streptomycin (Gibco), 1 nM insulin and 0.1% (w/v) foetal bovine serum (FBS) (Sigma). The study was approved by the Danish Animal Experiments Inspectorate under the Ministry of Food, Agriculture and Fisheries and in accordance with European Union directive 2010/63/ EU.
Each replicate performed in primary hepatocytes was a biological replicate, meaning that a new hepatocyte isolation from one rat was performed.
Western blot. Primary hepatocytes were plated in collagen-coated 6-well plates (1 000 000 cells/well) in culture medium as described above. The following day, the medium was changed to medium 199 supplemented with 100 nM Decadron, 1% (v/v) penicillin/ streptomycin and 0.1% (w/v) human serum albumin (HSA), and cells were starved for 7 hr, following pre-stimulation with SII Ang II (30 lM) or Ang II (100 nM) for 30 min. and/or insulin (10 nM for 5 min.).
In the experiments where inhibitors were used, cells were pre-treated for 1 hr with 10 lM 4-amino-3-(4-chlorophenyl)-1-(t-butyl)-1H-pyrazolo [3,4- 
Bonn, Institute of Pharmaceutical Biology) 1 hr prior to stimulation. Incubation was terminated by lysis of cells on ice for 30 min. in cell extraction buffer containing 10 mM Tris pH 7.4, 100 nM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 2 mM Na 3 VO 4 , 20 mM Na 4 P 2 O 7 , 1% Triton X-100, 10% glycerol, 0.1% SDS and 0.5% deoxycholate (Invitrogen) supplemented with 50 ll/ml protease inhibitor cocktail (Sigma P-2714) and 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AESBF) (CalbioChem). Lysates were centrifuged for 15 min. at 13 000 rpm, and protein content was determined by the bicinchoninic acid method [34] .
Equal amount of protein lysate was subjected to SDS-PAGE (4%-12% Bis-Tris gels) and transferred to nitrocellulose membranes and incubated with primary antibodies against Akt (pSer473), Akt (pThr308), FOXO1 (pSer256), IRb, phospho-Tyr 4G10, GSK3a/b (pSer21/9) or b-actin. All antibodies were from Cell Signaling, except anti-phosphotyrosine antibody, clone 4G10 (Millipore) and b-actin (Abcam). As secondary antibodies, horseradish peroxidase (HRP)-conjugated antibodies were used and the immunoblots were visualized on LAS3000 Fujifilm using the chemiluminescent substrate WesternBright HRP substrate (Advansta). Quantification was performed with ImageGauge 4.0 (Fujifilm).
Glycogen synthesis. Primary hepatocytes were plated in collagencoated 96-well plates (50 000 cells/well), and on the day of assay performance, the medium was changed to medium 199 supplemented with 0.5% (w/v) HSA. Cells were stimulated for 24 hr or 30 min. with 30 lM SII Ang II, 100 nM Ang II or 100 nM losartan after stimulation with insulin (10 lM) for 24 hr. Inhibitors, where used (4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo [3,4- [36] , 1 lM, were applied 30 min. prior to stimulation.
The stimulation was terminated by washing with ice-cold phosphate-buffered saline (PBS), and cells were cooled with liquid nitrogen to obtain lysis of the hepatocytes. Accumulated glycogen was digested by adding amyloglucosidase (Sigma) in 0.2 M acetate buffer (70 lL/ well) for 3 hr at 40°C; 40 ll of the mixture was transferred to 96-well plates (Costar 3635) and 10 lL 0.25 M NaOH was added. A glucose standard curve was included on each plate and glucose content was determined in a hexokinase/glucose-6-phosphate dehydrogenase assay [37] . Briefly, 200 lL assay buffer (0.2 M triethanolamine buffer supplemented with 7.5 mM MgCl 2 , 2.2 mM NADP, 2.2 mM ATP) was added to each well and the absorbance at 340 nM was measured in the presence or absence of hexokinase/glucose-6-phosphate dehydrogenase (Roche).
Glucose output assay. Hepatocytes were plated in 12-well plates (500 000 cells/well) in medium 199 without glucose and phenol red (Gibco) supplemented with 2 mM pyruvate. Cells were stimulated with Ang II (100 nM) or SII Ang II (30 lM) for 8 hr, after stimulation with insulin (30 nM) for 16 hr, or with insulin alone. The glucose content in the media was measured as described above.
IP-One assay. D-myo-inositol 1-phosphate (IP1) accumulation was measured in a homogeneous time-resolved fluorescence (HTRF) assay (Cisbio Bioassays). This assay is a competitive immunoassay, where intracellular IP1 inhibits fluorescence resonance energy transfer (FRET) signal that occurs when the IP1 derivative bearing the HTRF acceptor d2 (IP-d2) and the anti-IP1 monoclonal antibody labelled with the HTRF donor (Lumi4-Tb Cryptate) are in proximity. The assay was performed according to the manufacturer's protocol. Briefly, 30 000 cells were plated in collagen-coated 384-well plates. The following day, stimulation buffer and ligand serial dilution were added to the cells and incubated for 1 hr at 37°C. IP1-d2 and anti IP1-Lumi4-Tb Cryptate were added and cells were incubated for 1 hr at room temperature. The FRET signal (fluorescence ratio 665 nm/ 620 nm) was measured on Mithras LB reader.
pERK assay. Phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) (pThr202/pTyr204) was measured using the AlphaScreen SureFire assay (PerkinElmer). In this assay, antibody conjugated donor and acceptor beads are brought into close proximity in the presence of phosphorylated ERK1/2. Excitation of the donor bead leads to the release of singlet oxygen and energy transfer in the donor bead, resulting in emission of light at 520-620 nm.
The assay was performed according to the protocol provided by the manufacturer. Briefly, primary hepatocytes were plated (50 000 cells/ well) in collagen-coated 96-well plates. Next day, cells were starved in Medium 199 (Gibco) without FBS for 5 hr prior to pre-stimulation with Ang II (100 nM) or SII Ang II (30 lM) for 30 min. and/or insulin (10 nM), 5 min. After agonist removal, 50 uL lysis buffer (PerkinElmer) was added, and plates were agitated for 10-15 min. at room temperature; 5 uL of cell lysate was transferred to 384 OptiPlates (PerkinElmer), and 5 uL of acceptor bead/antibody solution was added. The plate was incubated for 2 hr at room temperature. Subsequently, 2 uL of donor bead solution was added and the plate was incubated for another 2 hr at room temperature. The fluorescent signal was measured on EnVision reader (PerkinElmer).
Data analysis. Data were analysed using GraphPad Prism. For the glycogen synthesis and Western blot studies where cells were treated with insulin AE AT1R ligands, statistical analyses were performed using one-way ANOVA and Dunnett's post-test, if not stated otherwise.
Results

SII Ang II increases insulin-mediated glycogen synthesis.
To assess the effects of AT1R ligands on glucose metabolism in liver, we examined the insulin-stimulated glycogen synthesis and insulin-mediated inhibition on glucose output in response to pre-treatment with either Ang II, SII Ang II, or the antagonist losartan in rat primary hepatocytes.
Short-term pre-treatment (30 min.) of primary hepatocytes with Ang II (100 nM) decreased insulin-stimulated glycogen synthesis, while SII Ang II (30 lM) and losartan (100 nM) did not significantly alter insulin-stimulated glycogen synthesis ( fig. 1A) . However, long-term pre-treatment with SII Ang II for 24 hr significantly increased insulin-stimulated glycogen synthesis (143% AE 15% compared to insulin treatment alone) (fig. 1B) . Long-term pre-treatment with Ang II or losartan did not significantly change insulin-stimulated glycogen synthesis compared to insulin treatment alone ( fig. 1B) . Neither Ang II nor SII Ang II alone had an effect on glycogen synthesis when compared to untreated conditions ( fig. 1A,B) .
We also measured the effect of SII Ang II on insulinmediated inhibition on hepatic glucose output by stimulating hepatocytes with 30 lM of SII Ang II or 100 nM Ang II for 8 hr after stimulation with insulin (30 nM, 16 hr) ( fig. 1C) . The insulin-inhibited glucose output was not significantly affected by pre-treatment with either SII Ang II or Ang II. Also, the treatment with the AT1R ligands alone did not affect glucose output compared to untreated condition ( fig. 1C) .
SII Ang II potentiates IR signalling. We analysed the molecular mechanism of action of SII Ang II and Ang II on IR signalling in primary rat hepatocytes. Firstly, we examined the effect of Ang II and SII Ang II on IR Tyr phosphorylation. As depicted in fig. 2A , insulin (10 nM, 5 min.) increased IR Tyr phosphorylation. Stimulation with Ang II (100 nM, 30 min.) after stimulation with insulin (10 nM, 5 min.) has a tendency to decrease Tyr phosphorylation of IR, but not significantly. Pre-treatment with SII Ang II (30 lM, 30 min.) did not significantly affect insulin-stimulated IR Tyr phosphorylation.
Secondly, we examined the effect of Ang II and SII Ang II on downstream IR signalling including Akt, GSK3a/b and FOXO1. Activation of IR by insulin (10 nM, 5 min.) led to phosphorylation (at Ser473 and Thr308) and activation of Akt ( fig. 2B and C) . Pre-treatment with Ang II (100 nM, 30 min.) had a tendency to increase phosphorylation at Akt Thr308 and Ser473, although the increase was not statistically significant. In contrast, pre-treatment with SII Ang II (30 lM, 30 min.) significantly potentiated insulin's effect on phosphorylation of Akt at Ser473 and had a tendency to increase phosphorylation at Thr308 sites (p = 0.053, one-way ANOVA, p < 0.05, Student's t-test when only comparing Ins and SII Ang II conditions). Treatment with Ang II or SII Ang II alone did not increase phosphorylation of Akt.
The phosphorylation of the Akt substrate GSK3a/b (pSer21/ 9) was also significantly increased by pre-stimulation with SII Ang II, but not Ang II when comparing to insulin treatment ( fig. 2D ). Stimulation with Ang II alone also increased phosphorylation of GSK3a/b, while stimulation with SII Ang II did not have an effect compared to the untreated conditions. The phosphorylation of FOXO1 (pSer 256) was not affected by pretreatment with Ang II or SII Ang II ( fig. 2E) .
Finally, we examined the effect of AT1R ligands on insulin-stimulated phosphorylation of ERK1/2 (pThr202/pTyr204). Phosphorylation of ERK1/2 (pThr202/pTyr204) increased in response to increasing concentration of insulin (5 min.) ( fig. 3) . Pre-treatment with Ang II (100 nM, 30 min.) increased the efficacy of insulin-stimulated phosphorylation of ERK/2 compared to insulin treatment (relative efficacy: 100 versus 118 AE 7, p = 0,03). Relative efficacies and pEC 50 values are reported in table 1. On the other hand, pre-treatment with SII Ang II (30 lM, 30 min.) significantly reduced the efficacy of insulin-stimulated ERK1/2 phosphorylation (relative efficacy: 100 versus 66 AE 3, p < 0.05). Increasing concentration of Ang II increased phosphorylation of ERK1/2 (pThr202/pTyr204), whereas SII Ang II had no effect.
SII Ang II potentiates insulin signalling via Src and Gaq.
Previously, it has been demonstrated that b-arrestin interacts with Src and that this interaction is necessary for the full activation of Akt [38] . We therefore examined the role of Src in the potentiating effect of SII Ang II on IR signalling. Treatment of hepatocytes with the Src inhibitor PP2 (10 lM, 1 hr) after stimulation with SII Ang II (30 lM, 30 min.) and subsequently insulin (10 nM, 5 min.) completely inhibited the potentiating effect of SII Ang II on phosphorylation of Akt (pSer473) and GSK3a/b (pSer21/9) ( fig. 4A and B) . In line with this, the presence of the Src inhibitor also reversed the potentiating effect of SII Ang II on insulin-stimulated glycogen synthesis ( fig. 4C ).
Angiotensin II type 1 receptor signalling activated by SII Ang II has been shown to be partially dependent on G protein activation in certain cells [39] . We therefore examined the role of Gaq protein in the potentiating effect of SII Ang II on insulin signalling. As shown in fig. 5 , Ang II stimulated IP1 accumulation dose-dependently, indicating robust Gaq signalling in hepatocytes. pEC 50 values and relative efficacies are reported in table 2. SII Ang II also stimulated IP1 accumulation but to a much lesser degree (21% of maximum Ang II response), while the antagonist losartan had no effect. Finally, the role of Gaq activation was assessed in the glycogen synthesis assay, where treatment with the Gaq inhibitor (UBO-QIC) reversed the potentiating effect of SII Ang II on glycogen synthesis ( fig. 6 ).
Discussion
Angiotensin II type 1 receptor signalling networks mediated by Ang II and SII Ang II have been analysed by global quantitative phosphoproteomics analysis [26, 27, 29] , where we and others have demonstrated that the functionally selective AT1R agonist SII Ang II regulates proteins that are central to IR signalling, including IR, Akt, GSK3a/b and ERK1/2. This led us to examine the role of SII Ang II on IR signalling and metabolism in primary hepatocytes, as the liver plays an important role in glucose metabolism. In the present study, we demonstrate that SII Ang II potentiates IR signalling by increasing insulin-stimulated phosphorylation of Akt and GSK3a/b, which further results in an increase in hepatic glycogen accumulation. Furthermore, treatment with SII Ang II (30 min.) decreases insulin-stimulated ERK phosphorylation, indicating that SII Ang II has differential effects on the two primary IR signalling pathways (PI3K/Akt and ERK1/2). Insulin phosphorylates and inactivates GSK3a/b and FOXO1, which are both downstream of Akt activation, leading to increased glycogen synthesis and inhibition of glucose output, respectively [2] [3] [4] . Here, we demonstrate that SII Ang II potentiates insulin-stimulated phosphorylation of Akt and GSK3a/b (fig. 2B,C and D) , while no effect is seen on FOXO1 phosphorylation (fig. 2E ). The differential effect of SII Ang II on GSK3a/b and FOXO1 phosphorylation could be explained if SII Ang II promotes different subcellular localization of Akt which favours phosphorylation and complex formation with GSK3a/b over FOXO1. Such complex formations have been demonstrated between b-arrestin-2, Akt, GSK3 and the protein phosphatase 2A (PP2A) upon dopamine D2 receptor activation. However, in this complex, PP2A is proposed to dephosphorylate Akt and thus acts as a negative regulator of Akt-GSK3b signalling pathway [40] . For the AT1R, formation of a similar complex has been indicated upon SII Ang II stimulation, but in contrast to the D2R complex, this complex facilitates increased Akt and GSK3b phosphorylation, which is in agreement with our data [27] . The increase in Akt and GSK3 phosphorylation in the b-arrestin-2-Akt-GSK3-PP2A complex is likely due to b-arrestin-2-mediated inhibition of PP2A via phosphorylation of the inhibitors of protein phosphatase 2A (I1PP2A) [27] .
Another explanation for the differential regulation of GSK3a/b and FOXO1 by SII Ang II in the presence of insulin may be due to differences in insulin sensitivity towards the two pathways. Thus, at the insulin concentrations used here (10 nM), SII Ang II may not be able to further potentiate insulin's effect on FOXO1 phosphorylation, as the maximum effect on FOXO1 phosphorylation has already been reached.
The observation that SII Ang II induces phosphorylation of GSK3a/b and not FOXO1 is in accordance with our findings demonstrating that SII Ang II potentiates insulin-stimulated glycogen synthesis, but does not alter the inhibition of hepatic glucose output by insulin ( fig. 1B and C) . However, we cannot exclude that under different conditions, such as prolonged pre-treatment with SII Ang II, the gluconeogenic pathway may also be affected. In the glucose output assay, cells were grown in glucose-free media, and longer treatment duration was not possible, as cell viability decreased with time.
Previous reports have shown that Ang II may lead to insulin resistance which is associated with a decrease in insulin-stimulated phosphorylation of Akt and other components of IR signalling in vascular smooth muscle cells and cardiomyocytes [16, 18, 41] . Another study has shown that Ang II-induced insulin resistance in liver is associated with increased IR signalling [42] , which is supported by our study demonstrating that Ang II decreases insulin-stimulated glycogen synthesis ( fig. 1A) , while potentially increasing phosphorylation of Akt and GSK3a/b ( fig. 2B and D) . Thus, the studies agree that Ang II has a negative effect on glucose homeostasis, but there is disagreement in whether Ang II increases or decreases IRmediated signalling through Akt. The discrepancies on whether Ang II increases or decreases activation of kinases involved in IR signalling may be due to tissue-specific effects or the duration of Ang II treatment. The importance of the duration of Ang II treatment is further supported by our findings demonstrating that while short-term treatment with Ang II decreases insulin-stimulated glycogen synthesis, long-term treatment with Ang II does not have an effect on glycogen synthesis.
SII Ang II has previously been thought to only engage barrestins [23] but as demonstrated in Sauliere et al. [39] , SII Ang II-mediated signalling may also partially be dependent on G protein activation in primary cardiac fibroblasts and mouse embryonic fibroblasts, where SII Ang II activates Gai and Gaq proteins and their downstream effectors to a certain degree. In this study, we examined the contribution of barrestin versus Gaq protein on SII Ang II-mediated potentiation of IR signalling. To examine the effect of b-arrestin, we have attempted to knock down b-arrestin by siRNA in primary hepatocytes but with insufficient effect. We therefore could not address the contribution of b-arrestin to the potentiating effect of SII Ang II on IR signalling and glycogen synthesis. However, it has been demonstrated that b-arrestin-2 knockdown in mice results in insulin resistance, while overexpression of b-arrestin-2 restored insulin sensitivity [38] . This indicates that b-arrestin may play a role in glucose metabolism. On the other hand, we found that the increase in insulinstimulated glycogen accumulation by SII Ang II pre-treatment is sensitive to Gaq inhibition ( fig. 6 ), even though SII Ang II does not activate Gaq signalling robustly in rat hepatocytes ( fig. 5) , as demonstrated by IP1 accumulation. Thus, the Gaq protein plays a role in the potentiating effect of SII Ang II on Fig. 3 . Effect of Ang II and SII Ang II on insulin-stimulated phosphorylation of ERK1/2. Phosphorylation of ERK1/2 (pThr202/pTyr204) was determined in hepatocytes after incubation (5 min.) with increasing concentration of insulin (Ins) alone (black), or after pre-incubation with Ang II (100 nM, 30 min.) (red) or SII Ang II (30 lM for 30 min.) (blue). Phosphorylation of ERK1/2 (pThr202/pTyr204) was also determined in the absence of insulin with increasing concentrations of Ang II (30 min.) (grey) or SII Ang (30 min.) (purple). Phosphorylated ERK1/2 (pThr202/pTyr204) is measured using AlphaScreen SureFire assay (PerkinElmer) and is shown relative to the maximal insulin response. Data are average of five independent experiments AE S.E.M. increased hepatic glucose output, decreased insulin-stimulated hepatic glucose uptake and impaired hepatic glycogen accumulation [1, 43] . By increasing insulin-stimulated glycogen accumulation, functionally selective AT1R agonists could potentially have beneficial effects on blood glucose levels. Although further research is necessary to establish the role of functionally selective AT1R agonist on glucose homeostasis, our findings raise an interesting question: Are functionally selective AT1R ligands potential candidates for treatment of metabolic disorders which are often associated with cardiovascular complications? Functionally selective AT1R agonists have several positive effects on cardiovascular tissue, including positive ionotropic effects and by facilitating cardioprotection [19, 24, 31] . Recently, functionally selective AT1R ligands (TRV023, TRV026, TRV027) that are up to 30 times more potent than SII Ang II were developed [44] . In humans and rodents, the TRV ligands decrease blood pressure and enhance ionotropic effects [32, 44] , which is consistent with studies with SII Ang II. In a canine heart failure model, TRV027 reduces systemic and renal vascular resistance and increases glomerular filtration rate, cardiac output and Na + and K + excretion [45] . However, long-term treatment with functionally selective AT1R agonists in rodents increases Na + retention, and thus, chronic treatment with these drugs may not be suitable [46] . Furthermore, chronic treatment with TRV027 increases cardiac performance in human subjects [32] . Although this effect may be beneficial in settings such as acute heart failure, it will most likely lead to overload of the heart and hypertrophy upon chronic treatment. Clinical trials with TRV027 began in 2010 and reached Phase IIb in clinical trial for treatment of acute decompensated heart failure, but the trial has now been terminated. The potentially negative effects of chronic treatment with TRV027 on cardiac function will most likely complicate its use in metabolic disorders, which will likely require chronic treatment with functionally selective AT1R compounds.
In conclusion, our study demonstrates that the functional selective AT1R agonist SII Ang II potentiates IR signalling and insulin-mediated glycogen synthesis in primary hepatocytes upon chronic treatment with SII Ang II. These effects are dependent on Src and Gaq, thus demonstrating a role of Gaq activation by SII Ang II in hepatocytes. 
